Trial Profile
Long-Term Follow-Up Study of Subjects Treated With an Autologous T Cell Product Expressing an Antibody-Coupled T-Cell Receptor (ACTR)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 13 Oct 2021
Price :
$35
*
At a glance
- Drugs ACTR 087/Rituximab combination therapy (Primary)
- Indications B-cell lymphoma; Multiple myeloma; Solid tumours
- Focus Adverse reactions
- Sponsors Cogent Biosciences
- 04 Oct 2021 Status changed from recruiting to discontinued due to business decision.
- 13 Oct 2016 Status changed from not yet recruiting to recruiting.
- 26 Jul 2016 New trial record